GERON CORP Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
GERON CORP (GERN) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $16.00 thousand as of 2014-12-31, per its 10-K filed 2016-03-10.
Discontinued › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2016-03-10
- 2014-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $16.00K.
- 2014-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.00K.
- 2014-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $290.00K.
- 2014-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $143.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2014-12-31 | $16.00K 10-K · filed 2016-03-10 |
| 2014-09-30 | $1.00K 10-Q · filed 2014-11-05 |
| 2014-06-30 | $290.00K 10-Q · filed 2014-08-11 |
| 2014-03-31 | $143.00K 10-Q · filed 2014-05-01 |
| 2013-12-31 | $367.00K 10-K · filed 2015-03-11 |
| 2013-09-30 | $258.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | $50.00K 10-Q · filed 2013-08-08 |
| 2012-12-31 | $51.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |